A randomized phase III trial of IV carboplatin and paclitaxel x 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: A Gynecologic Oncology Group Study

Gynecologic Oncology

Volumn 122, Issue 1, 2011, Pages 89-94

  Mannel, Robert S ^a   Brady, Mark F ^b   Kohn, Elise C ^c   Hanjani, Parviz ^d   Hiura, Masamichi ^e   Lee, Roger ^f   DeGeest, Koen ^g   Cohn, David E ^h   Monk, Bradley J ⁱ   Michael, Helen ^j  

^a UNIVERSITY OF OKLAHOMA   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d ABINGTON MEMORIAL HOSPITAL   (United States)

^e NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^f Tacoma General Hospital   (United States)

^g UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^h OHIO STATE UNIVERSITY   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

early stage ovarian carcinoma; GOG; IV carboplatin and paclitaxel

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; AGED; ANEMIA; ATOPIC DERMATITIS; BLEEDING; BLOOD CLOTTING DISORDER; CANCER INCIDENCE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; DOSAGE SCHEDULE COMPARISON; DRUG HYPERSENSITIVITY; DRUG SAFETY; EAR DISEASE; ENDOCRINE DISEASE; EYE DISEASE; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; HUMAN; LEUKOPENIA; LIVER DISEASE; LOW DRUG DOSE; LUNG DISEASE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; METABOLIC DISORDER; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NEUTROPENIA; OVARY CARCINOMA; PAIN; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEXUAL DYSFUNCTION; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UROGENITAL TRACT DISEASE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PACLITAXEL; TREATMENT OUTCOME;

EID: 79957725785     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.03.013     Document Type: Conference Paper

References (27)

1. Young RC, Walton LA, Ellenberg SS, et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. N Engl J Med 1990;322:1021-7.
2. 32P or intravenous cyclophosphamide and cisplatin: a Gynecologic Oncology Group study. J Clin Oncol 2003;21:4350-5.
3. 32P). GICOG: Gruppo Interregionale Collaborativo in Ginecologia Oncologica. Ann Oncol 1995;6:887-93.
4. Vergote IB, Vergote-De Vos LN, Abeler VM, et al. Randomized trial comparing cisplatin with radioactive phosphorus or whole-abdomen irradiation as adjuvant treatment of ovarian cancer. Cancer 1992;69:741-9.
5. Trimbos JB, Parmar M, Vergote I, et al. International collaborative ovarian neoplasm trial I and adjuvant chemotherapy in ovarian neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in early-stage ovarian carcinoma. J Natl Cancer Inst 2003;5:105-12. (Pubitemid 36196730)
6. Trimbos JB, Vergote I, Bolis G, et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organization for Research and Treatment of Cancer - adjuvant chemotherapy in ovarian neoplasm trial. J Natl Cancer Inst 2003;95:113-25. (Pubitemid 36193260)
7. Bell J, Brady MF, Young RC, et al. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early-stage ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2006;102:432-9. (Pubitemid 44353663)
8. DuBois A, Quinn M, Thigpen T, et al. Consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIGOCCC 2004). Ann Oncol 2004;16:viii7-viii12 10.1093.
9. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6. (Pubitemid 26012496)
10. Ozols R, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally-resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21:3194-200. (Pubitemid 46606249)
11. Paley PJ, Staskus KA, Gebhard K, et al. Vascular endothelial growth factor expression in early-stage ovarian cancer. Cancer 1997;80:98-106. (Pubitemid 27270925)
12. Hollingsworth HC, Kohn EC, Steinberg SM, et al. Tumor angiogenesis in advanced stage ovarian carcinoma. Am J Path 1995;147:33-41.
13. Belotti D, Vergani V, Drudis T, et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 1996;2:1843-9. (Pubitemid 26384151)
14. Wang J, Lou P, Lesniewski R, et al. Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anticancer Drugs 2003;14:13-9. (Pubitemid 36177350)
15. Klauber N, Parangi S, Flynn E, et al. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 1997;57:81-6. (Pubitemid 27021522)
16. Markman M, Liu PY, Wilczynski S, et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003;21:2460-5. (Pubitemid 46606325)
17. Katsumata N, Yasuda M, Takahasi F, et al. Dose-dense paclitaxel once-a-week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase III, open-label, randomized controlled trial. Lancet 2009;374:1331-8.
18. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemotherapy Rep 1966;50:163-70.
19. Schoenfeld D. The asymptotic properties of comparative tests for comparing survival distributions. Biometrika 1981;68:316-9.
20. Chan JK, Tian C, Fleming GF, et al. The potential benefit of six versus three cycles of chemotherapy in subsets of women with early-stage high risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study. Gynecol Oncol 2010;116:301-6.
21. Zorn KK, Bonome T, Gangi L, et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res 2005;11:6422-30. (Pubitemid 41338978)
22. Stany MP, Bonome T, Wamunyokoli F, et al. Classification of ovarian cancer: a genomic analysis. Adv Exp Med Biol 2008;622:22-33.
23. Farley J, Ozbun LL, Birrer MJ. Genomic analysis of epithelial ovarian cancer. Cell Res 2008;18:538-48. (Pubitemid 351630950)
24. Bookman M, Brady M, McGuire W, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup. J Clin Oncol 2009;27:1419-25.
25. Takano M, Sugiyama T, Yaegashi N, et al. Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel- carboplatin or irinotecan - cisplatin: retrospective analysis. Int J Clin Oncol 2007;12:256-60. (Pubitemid 47262735)
26. Kurman RJ, Shih IeM. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol 2008;27:151-60. (Pubitemid 351450677)
27. Yoshida S, Furukawa N, Haruta S, et al. Theoretical model of treatment strategies for clear cell carcinoma of the ovary: focus on perspectives. Cancer Treat Rev 2009;35:608-15.